glp-1 obesity drug news today sep 30 2025 This new Medicare program offers drugs for $50 a month. Here’s what you need to know This new Medicare program offers
Description
Recent developments underscore the relevance of GLP-1R agonists in addressing the complex interplay of cardiovascular-kidney-metabolic (CKM) syndrome, microvascular dysfunction, and metabolic-associated steatohepatitis (MASH)
Remove patch and discard
A new FDA-approved obesity pill could offer a lower-cost alternative to injectable GLP-1 drugs like Ozempic and Mounjaro
The purpose of this chapter is to provide the healthcare practitioner with an overview of the existing oral and injectable (non-insulin) pharmacological options available for the treatment of patients with T2DM
The magnitude of the benefits of GLP-1RA and SGLT-2 inhibitors on MACE are similar, ranging from 12 to 14% reduction of risk, but only GLP-1RA may reduce the risk of stroke
Your Questions about Ozempic and Mounjaro for weight loss are answered
